NCT07392372RecruitingPhase 1
A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 10 Oct 2025
- Start date
- 9 Feb 2026
- Lead sponsor
- BioNTech SE
- Diseases
- HIV
- EU CT number
- 2025-523846-29-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 50
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Koeln AöR Coordinator of this site? Confirm its status | Cologne | Germany | Recruiting |
| CRS Clinical Research Services Mannheim GmbH Coordinator of this site? Confirm its status | Mannheim | Germany | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.